pmc logo image
Logo of jpnSubmit a ManuscriptEmail AlertsAbout JPNJournal of Psychiatry and Neuroscience
Journal List > J Psychiatry Neurosci > v.19(2); Mar 1994

Formats:
J Psychiatry Neurosci. 1994 March; 19(2): 109–113.
PMCID: PMC1188574
Copyright notice
Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.
G Faludi, K Tekes, and L Tóthfalusi
Semmelweis Medical University, Department of Psychiatry, Budapest, Balassa, Hungary.
Abstract
High affinity 3H-paroxetine and 3H-imipramine binding sites were simultaneously studied in platelets of 29 untreated patients with panic disorder and 12 healthy controls. The maximum number of binding sites (Bmax) was found to be significantly lower in the panic patients compared to the controls using either ligand. No difference in the Kd values between the groups of subjects was found. The disturbance of serotonin neurotransmission in panic disorder--decrease in Bmax values--may be either a consequence or a reason of serotonergic dysfunction.
Full text
Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (742K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.
 
icon of scanned page 109
109
icon of scanned page 110
110
icon of scanned page 111
111
icon of scanned page 112
112
icon of scanned page 113
113
 
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
  • Bäckström IT, Marcusson JO. 5-Hydroxytryptamine-sensitive [3H]imipramine binding of protein nature in the human brain. I. Characteristics. Brain Res. 1987 Nov 3;425(1):128–136. [PubMed]
  • Bäckström I, Bergström M, Marcusson J. High affinity [3H]paroxetine binding to serotonin uptake sites in human brain tissue. Brain Res. 1989 May 8;486(2):261–268. [PubMed]
  • Bénavidès J, Savaki HE, Malgouris C, Laplace C, Margelidon C, Daniel M, Courteix J, Uzan A, Guérémy C, Le Fur G. Quantitative autoradiography of [3H]indalpine binding sites in the rat brain: I. Pharmacological characterization. J Neurochem. 1985 Aug;45(2):514–520. [PubMed]
  • Biessen EA, Norder JA, Horn AS, Robillard GT. Evidence for the existence of at least two different binding sites for 5HT-reuptake inhibitors within the 5HT-reuptake system from human platelets. Biochem Pharmacol. 1988 Oct 15;37(20):3959–3966. [PubMed]
  • Coplan JD, Gorman JM, Klein DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology. 1992 May;6(3):189–200. [PubMed]
  • D'Amato RJ, Largent BL, Snowman AM, Snyder SH. Selective labeling of serotonin uptake sites in rat brain by [3H]citalopram contrasted to labeling of multiple sites by [3H]imipramine. J Pharmacol Exp Ther. 1987 Jul;242(1):364–371. [PubMed]
  • D'haenen H, De Waele M, Leysen JE. Platelet 3H-paroxetine binding in depressed patients. Psychiatry Res. 1988 Oct;26(1):11–17. [PubMed]
  • Demushkin VP, Fomenko AM, Plyashkevich YG, Shchurin MR, Brusov OS. High- and low-affinity [3H]imipramine binding sites on human platelets: separate determination and involvement of sulphur-containing bonds. Eur J Pharmacol. 1987 Aug 11;140(2):171–178. [PubMed]
  • Hrdina PD. Differentiation of two components of specific [3H]imipramine binding in rat brain. Eur J Pharmacol. 1984 Jul 20;102(3-4):481–488. [PubMed]
  • Hrdina PD. Imipramine binding sites in brain and platelets: role in affective disorders. Int J Clin Pharmacol Res. 1989;9(2):119–122. [PubMed]
  • Innis RB, Charney DS, Heninger GR. Differential 3H-imipramine platelet binding in patients with panic disorder and depression. Psychiatry Res. 1987 May;21(1):33–41. [PubMed]
  • Klompenhouwer JL, Fekkes D, van Hulst AM, Moleman P, Pepplinkhuizen L, Mulder PG. Seasonal variations in binding of 3H-paroxetine to blood platelets in healthy volunteers: indications for a gender difference. Biol Psychiatry. 1990 Sep 15;28(6):509–517. [PubMed]
  • Lewis DA, Noyes R, Jr, Coryell W, Clancy J. Tritiated imipramine binding to platelets is decreased in patients with agoraphobia. Psychiatry Res. 1985 Sep;16(1):1–9. [PubMed]
  • Marcusson J, Tiger G. [3H]imipramine binding of protein nature in human platelets: inhibition by 5-hydroxytryptamine and 5-hydroxytryptamine uptake inhibitors. J Neurochem. 1988 Apr;50(4):1032–1036. [PubMed]
  • Marazziti D, Rotondo A, Placidi GF, Perugi G, Cassano GB, Pacifici GM. Imipramine binding in platelets of patients with panic disorder. Pharmacopsychiatry. 1988 Jan;21(1):47–49. [PubMed]
  • Mellerup ET, Plenge P, Engelstoft M. High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes. Eur J Pharmacol. 1983 Dec 23;96(3-4):303–309. [PubMed]
  • Mellerup ET, Plenge P, Nielsen M. Size determination of binding polymers for [3H]imipramine and [3H]paroxetine in human platelet membranes. Eur J Pharmacol. 1984 Nov 13;106(2):411–413. [PubMed]
  • Mellerup ET, Plenge P. High affinity binding of 3H-paroxetine and 3H-imipramine to rat neuronal membranes. Psychopharmacology (Berl). 1986;89(4):436–439. [PubMed]
  • Nutt DJ, Fraser S. Platelet binding studies in panic disorder. J Affect Disord. 1987 Jan–Feb;12(1):7–11. [PubMed]
  • Peterson GL. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem. 1977 Dec;83(2):346–356. [PubMed]
  • Plenge P, Mellerup ET, Rafaelsen OJ. Chlorimipramine--but not imipramine--rapidly reduces imipramine--but not paroxetine--binding in human platelets. Clin Neuropharmacol. 1986;9 Suppl 4:113–115. [PubMed]
  • Pletscher A. Platelets as models: use and limitations. Experientia. 1988 Feb 15;44(2):152–155. [PubMed]
  • Raisman R, Cash R, Agid Y. Parkinson's disease: decreased density of 3H-imipramine and 3H-paroxetine binding sites in putamen. Neurology. 1986 Apr;36(4):556–560. [PubMed]
  • Schneider LS, Munjack D, Severson JA, Palmer R. Platelet [3H]imipramine binding in generalized anxiety disorder, panic disorder, and agoraphobia with panic attacks. Biol Psychiatry. 1987 Jan;22(1):59–66. [PubMed]
  • Segonzac A, Schoemaker H, Langer SZ. Temperature dependence of drug interaction with the platelet 5-hydroxytryptamine transporter: a clue to the imipramine selectivity paradox. J Neurochem. 1987 Feb;48(2):331–339. [PubMed]
  • Uhde TW, Berrettini WH, Roy-Byrne PP, Boulenger JP, Post RM. Platelet [3H]imipramine binding in patients with panic disorder. Biol Psychiatry. 1987 Jan;22(1):52–58. [PubMed]
  • Weizman A, Carel C, Tyano S, Rehavi M. Decreased high affinity 3H-imipramine binding in platelets of enuretic children and adolescents. Psychiatry Res. 1985 Jan;14(1):39–46. [PubMed]
  • Weizman R, Carmi M, Tyano S, Apter A, Rehavi M. High affinity [3H]imipramine binding and serotonin uptake to platelets of adolescent females suffering from anorexia nervosa. Life Sci. 1986 Mar 31;38(13):1235–1242. [PubMed]
  • Weizman A, Carmi M, Hermesh H, Shahar A, Apter A, Tyano S, Rehavi M. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. Am J Psychiatry. 1986 Mar;143(3):335–339. [PubMed]
Articles from Journal of Psychiatry & Neuroscience : JPN are provided here courtesy of
Canadian Medical Association

PubMed articles by these authors